Evidence map›Paper›PMID 39259751›Full record

ArticlePLoS pathogens2024

Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.

William J Cisneros, Shimaa H A Soliman, Miriam Walter, Lacy M Simons, Daphne Cornish, Simone De Fabritiis, Ariel W Halle, Eun-Young Kim, Steven M Wolinsky, Ramon Lorenzo-Redondo and 2 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

William J CisnerosDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.ORCID 0000-0003-2472-6167
Shimaa H A SolimanSimpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Miriam WalterDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Lacy M SimonsDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Daphne CornishDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Simone De FabritiisSimpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Ariel W HalleDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Eun-Young KimDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Steven M WolinskyDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Ramon Lorenzo-RedondoDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Ali ShilatifardSimpson Querrey Institute for Epigenetics, Department of Biochemistry and Molecular Genetics Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Judd F HultquistDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.ORCID 0000-0001-6424-4280

Funding

Virology and Immunology Technology CoreP30AI117943 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Mohamed Abdel Mohsen · 2015 to 2026
$38.4M
Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALAN D FRANKEL · 2022 to 2026
$35.7M
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS ResearchU01HL146240 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Frank J Palella, Valentina Stosor · 2019 to 2026
$31.5M
CELLULAR &MOLECULAR BASIS OF DISEASE TRAINING PROGRAMT32GM008061 · NIGMS · NORTHWESTERN UNIVERSITY · PI CARTHEW, RICHARD W. · 1985 to 2022
$17.1M
Unraveling the Mechanisms of HIV Persistence and ReboundP01AI169600 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Thomas Hope · 2022 to 2026
$9.3M
Functionally Defining HIV-Host Interactions During the Early HIV-1 LifecycleR01AI150998 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIENIASZ, PAUL D., HOPE, THOMAS · 2020 to 2024
$6.8M
Role of myeloid cells in CNS and systemic reservoirs and reboundR01MH125778 · NIMH · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Thomas Hope, Ramon Lorenzo-Redondo · 2022 to 2026
$5.1M
Turning off HIV White Noise: Switching from Long-Lived to Short-Lived ReservoirR01AI176599 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Elena Martinelli · 2023 to 2026
$4.7M
Regulation of SAMHD1 antiviral activityR01AI150455 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI DIAZ-GRIFFERO, FELIPE · 2019 to 2024
$3.3M
Deciphering the Role of CPSF6 in HIV InfectionR01AI165236 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F · 2021 to 2025
$2.0M
Controlling HIV latency by manipulating CycT1 turnoverR01AI167778 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FUJINAGA, KOH · 2022 to 2025
$1.6M
Exploring Small Molecule Inhibitors of PAF1C as Novel HIV Latency Reversal AgentsR21AI174864 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HULTQUIST, JUDD F, SHILATIFARD, ALI · 2023 to 2024
$426k
NHLBI NIH HHS U01 HL146240NIAID NIH HHS P01 AI169600NIAID NIH HHS P30 AI117943NIAID NIH HHS R01 AI150455NIAID NIH HHS R01 AI150998NIAID NIH HHS R01 AI165236NIAID NIH HHS R01 AI167778NIAID NIH HHS R01 AI176599NIAID NIH HHS R21 AI174864NIAID NIH HHS U54 AI170792NIGMS NIH HHS T32 GM008061NIMH NIH HHS R01 MH125778
6 · The paper itself

Abstract

The persistence of HIV-1 in long-lived latent reservoirs during suppressive antiretroviral therapy (ART) remains one of the principal barriers to a functional cure. Blocks to transcriptional elongation play a central role in maintaining the latent state, and several latency reversal strategies focus on the release of positive transcription elongation factor b (P-TEFb) from sequestration by negative regulatory complexes, such as the 7SK complex and BRD4. Another major cellular reservoir of P-TEFb is in Super Elongation Complexes (SECs), which play broad regulatory roles in host gene expression. Still, it is unknown if the release of P-TEFb from SECs is a viable latency reversal strategy. Here, we demonstrate that the SEC is not required for HIV-1 replication in primary CD4+ T cells and that a small molecular inhibitor of the P-TEFb/SEC interaction (termed KL-2) increases viral transcription. KL-2 acts synergistically with other latency reversing agents (LRAs) to reactivate viral transcription in several cell line models of latency in a manner that is, at least in part, dependent on the viral Tat protein. Finally, we demonstrate that KL-2 enhances viral reactivation in peripheral blood mononuclear cells (PBMCs) from people living with HIV (PLWH) on suppressive ART, most notably in combination with inhibitor of apoptosis protein antagonists (IAPi). Taken together, these results suggest that the release of P-TEFb from cellular SECs may be a novel route for HIV-1 latency reactivation.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsPositive Transcriptional Elongation Factor BVirus LatencyGene Expression Regulation, ViralHumansVirus ActivationVirus ReplicationPositive Transcriptional Elongation Factor B

Identifiers

PMID39259751
PMCPMC11419360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.